Ocrelizumab for Psychosis by Autoimmunity
Phase 1/2
40
about 6.1 years
18–35
1 site in TX
About this study
This trial is testing whether ocrelizumab, a medication that suppresses auto-antibodies, can help people with psychosis caused by autoimmune factors. Participants will receive ocrelizumab infusions and undergo evaluations to assess the treatment's effects on their symptoms and cognitive function. It aims to determine if this approach is effective in managing psychosis related to auto-antibody production.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Physical and neuro-cognitive evaluations
- 2.Participate in Psychosis and cognitive assessments
- 3.Receive Ocrelizumab infusion
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ocrelizumab
injection, intravenous, infusion
Secondary: Score on quality of life scales for psychiatric patients
diagnostic
Psychiatry / Mental Health